Research programme: ROR gamma antagonists - Orca Pharmaceuticals
Alternative Names: Autoimmune disorder therapeutics - Orca Pharmaceuticasl; BBI-6000; ROR gamma antagonists; ROR gammat inhibitors; RORγt inhibitorsLatest Information Update: 14 Sep 2022
At a glance
- Originator New York University
- Developer New York University; Orca Pharmaceuticals; University of Oxford
- Class Small molecules
- Mechanism of Action Nuclear receptor subfamily 1 group F member 3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 07 Sep 2022 Brickell Biotech Inc is now called Fresh Tracks Therapeutics
- 31 Aug 2019 Brickell Biotech has merged with Vical to form Brickell Biotech Inc, and subsequently Brickell Biotech changed its name to Brickell Subsidiary
- 28 Jul 2018 No recent reports of development identified for preclinical development in Autoimmune-disorders in United Kingdom (PO)